glp-1 drugs long term side effects Medications Infographic Glucagon-like Receptor-1 agonists for obesity:

These hormones then signal the pancreas to release insulin

Food tolerability returns to near-normal levels

Call us for a free consultation

Topline Eli Lilly and Novo Nordisk will cut prices of their obesity drugs and Medicare will begin covering the drugs for some patients beginning next year, pursuant to a deal President Donald Trump announced Thursday with the drug companies

Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy

However, any new medication must be carefully assessed for its potential impact on mood stability and its compatibility with existing bipolar disorder treatments